Is Moderna Stock Overvalued -- or a Bargain?

Moderna (NASDAQ: MRNA) shares have soared over the past year. Investors bet on the company's ability to bring a vaccine to market -- and then make billions of dollars in revenue. In this Motley Fool Live video recorded on May 28, 2021, Healthcare and Cannabis Bureau Editor and Analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss Moderna's valuation and whether there is still room for the biotech stock to gain over the long term.

Continue reading

Source Fool.com